FDA expands Vetmedin’s role in preclinical canine heart disease

Version 1 — Brief

Boehringer Ingelheim’s pimobendan products, Vetmedin Chewable Tablets and Vetmedin Solution, have now received FDA approval to delay the onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease, expanding beyond the earlier conditional approval pathway and making this the first FDA-approved drug for that indication. Today’s Veterinary Business flagged the move in its January 26, 2026, breaking news roundup, and the FDA said the approval supplements the existing Vetmedin approval for dogs with Stage B2 preclinical MMVD. Veterinary Practice News, meanwhile, pointed to the broader cost pressures clinics are facing, including expected tariff-related increases for drugs, supplies, and equipment, as well as wider industry strains such as consolidation among major distributors and ongoing vaccine hesitancy that can complicate client communication. (todaysveterinarybusiness.com)

Why it matters: For veterinary professionals, this is a meaningful cardiology update because it formalizes an earlier-intervention option for dogs with asymptomatic but structurally significant MMVD, a common condition in general practice. It also gives clinics a fully approved label to support client conversations around screening, echocardiographic staging, adherence, and long-term monitoring, even as practices navigate higher input costs that could affect pricing and access. The broader backdrop matters too: if supply costs rise and trust in preventive medicine remains uneven, hospitals may need even clearer, more consistent messaging around evidence-based recommendations. (fda.gov)

What to watch: Watch for how quickly general practices and cardiology services adjust Stage B2 screening, prescribing, and pet parent education now that both tablet and liquid formulations carry the indication, and whether economic pressure or broader client skepticism affects uptake of recommended diagnostics and long-term therapy. (animalhealth.boehringer-ingelheim.com)